Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in adults age 18 and older compared with its original vaccine, Spikevax.

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

Moderna has filed complaints in the US and Germany claiming that the mRNA technology used to make Pfizer and BioNTech's Comirnaty vaccine infringes multiple patents that cover its own Spikevax shot.

As proven by the success of the Spikevax COVID-19 vaccine, Moderna aims to build on this achievement by expanding into applications for influenza, cancer, and rare diseases. In recent years ...

The new vaccine is an updated version of Moderna's widely-use Spikevax vaccine, which includes sequences from the original Wuhan strain of SARS-CoV-2, as well as from the Omicron BA.1 subvariant.

In its fourth quarter of 2025, Moderna reported $923 million in Spikevax sales, comprised of $244 million in the United States and $679 million internationally. Spikevax generated $3.1 billion in ...

sued Moderna in the District of Delaware alleging that Moderna infringed several patents based on its sales of Spikevax®. This case, which involved Arbutus’ patented lipid nanoparticle (LNP ...

Recent legal challenges have put Moderna in a spotlight ... affecting products like Spikevax®. This ongoing legal tussle has impacted investor sentiment, contributing to the company's share ...

Best known for its COVID-19 vaccine, Spikevax, Moderna also has a broad pipeline targeting respiratory, latent, and enteric viruses, as well as cancer and rare diseases. MRNA is expected to ...